Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors within the central nervous program, conolidine modulates alternate molecular targets. A Science Innovations examine observed that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availabili... https://williamk109qfs7.therainblog.com/profile